Wang TF, Chen Q, Deng J, Li SL, Xu Y, Ma SX. Research progress on venous thrombosis development in patients with malignant tumors. World J Clin Cases 2024; 12(11): 1900-1908 [PMID: 38660542 DOI: 10.12998/wjcc.v12.i11.1900]
Corresponding Author of This Article
Si-Xing Ma, PhD, Chief Physician, Department of Vascular Surgery, The Affiliated Hospital of Guizhou Medical University, No. 28 Guimedical Street, Yunyan District, Guiyang 550000, Guizhou Province, China. masixing168@163.com
Research Domain of This Article
Health Policy & Services
Article-Type of This Article
Minireviews
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Clin Cases. Apr 16, 2024; 12(11): 1900-1908 Published online Apr 16, 2024. doi: 10.12998/wjcc.v12.i11.1900
Research progress on venous thrombosis development in patients with malignant tumors
Teng-Fei Wang, Qian Chen, Jie Deng, Shi-Liang Li, Yuan Xu, Si-Xing Ma
Teng-Fei Wang, Jie Deng, Shi-Liang Li, Si-Xing Ma, Department of Vascular Surgery, The Affiliated Hospital of Guizhou Medical University, Guiyang 550000, Guizhou Province, China
Qian Chen, Yuan Xu, Department of Organ Transplantation, The Affiliated Hospital of Guizhou Medical University, Guiyang 550000, Guizhou Province, China
Author contributions: Wang TF and Chen Q conceived and presented the idea; Deng J, Xu Y and Ma SX wrote the manuscript with the support of Ma SX, Xu Y, Li SL and Wang TF; Ma SX supervised the results of this work; Ma SX oversaw the process and was responsible for the overall planning and management. All authors discussed the results and contributed to the final manuscript.
Supported byGuizhou Provincial Basic Research Program, No. ZK2023376; Guizhou Provincial Health Commission Science and Technology Fund Project, No. GZWKJ2023164 and No. SYXK2018-0001; and Guizhou Medical University Hospital National Natural Science Foundation Cultivation Project, No. GYFYnsfc-2021-36.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Si-Xing Ma, PhD, Chief Physician, Department of Vascular Surgery, The Affiliated Hospital of Guizhou Medical University, No. 28 Guimedical Street, Yunyan District, Guiyang 550000, Guizhou Province, China. masixing168@163.com
Received: January 15, 2024 Peer-review started: January 15, 2024 First decision: February 23, 2024 Revised: March 4, 2024 Accepted: March 20, 2024 Article in press: March 20, 2024 Published online: April 16, 2024 Processing time: 86 Days and 19.3 Hours
Abstract
The coexistence of venous thromboembolism (VTE) within patients with cancer, known as cancer-associated thrombosis (CAT), stands as a prominent cause of mortality in this population. Over recent years, the incidence of VTE has demonstrated a steady increase across diverse tumor types, influenced by several factors such as patient management, tumor-specific risks, and treatment-related aspects. Furthermore, mutations in specific genes have been identified as potential contributors to increased CAT occurrence in particular cancer subtypes. We conducted an extensive review encompassing pivotal historical and ongoing studies on CAT. This review elucidates the risks, mechanisms, reliable markers, and risk assessment methodologies that can significantly guide effective interventions in clinical practice.
Core Tip: Treatment-related risks involve therapies such as chemotherapy, endocrine therapy, angiogenesis inhibitors, immunotherapy, protein kinase inhibitors, blood transfusions, and cell line stimulants, all contributing to venous thromboembolism. This review summarizes the pathogenesis of cancer-associated thrombosis and treatment approaches for this condition. This review elucidates the risks, mechanisms, reliable markers, and risk assessment methodologies that can significantly guide effective interventions in clinical practice.
